Abstract:Cell-intrinsic reporters such as luciferase (LUC) and red fluorescent protein (RFP) have been commonly utilized in preclinical studies to image tumor growth and to monitor therapeutic responses. While extrinsic reporters that emit near infrared I (NIR-I: 650-950 nm) or near-infrared II (NIR-II: 1000 -1700 nm) optical signals have enabled minimization of tissue autofluorescence and light scattering, it has remained unclear as to whether their use has afforded more accurate tumor imaging in small animals. Here, we developed a novel optical imaging construct comprised of rare earth lanthanide nanoparticles coated with biodegradable diblock copolymers and doped with organic fluorophores, generating NIR-I and NIR-II emissive bands upon optical excitation. Simultaneous injection of multiple spectrally-unique nanoparticles into mice bearing tumor implants established via intraperitoneal dissemination of LUC+/ RFP+ OVCAR-8 ovarian cancer cells enabled direct comparisons of imaging with extrinsic vs. intrinsic reporters, NIR-II vs. NIR-I signals, as well as targeted vs. untargeted exogenous contrast agents in the same animal and over time. We discovered that in vivo optical imaging at NIR-II wavelengths facilitates more accurate detection of smaller and earlier tumor deposits, offering enhanced sensitivity, improved spatial contrast, and increased depths of tissue penetration as compared to imaging with visible or NIR-I fluorescent agents. Our work further highlights the hitherto underappreciated enhancements in tumor accumulation that may be achieved with intraperitoneal as opposed to intravenous administration of nanoparticles. Lastly, we found discrepancies in the fidelity of tumor uptake that could be obtained by utilizing small molecules for in vivo as opposed to in vitro targeting of nanoparticles to disseminated tumors. (C) 2017 Elsevier Ltd. All rights reserved.

Fcla-Enhanced Sonoluminescence Imaging In Vivo

&Lt;title>sonoluminescence Imaging in Vivo</title>

In Vivo Sonoluminescence Imaging with the Assistance of FCLA

Sonoluminescence Imaging and Its Biomedical Applications

&Lt;title>enhanced Sonoluminescence of Tissues</title>

FCLA Chemiluminescence from Sonodynamic Action in Vitro and in Vivo

Early Tumor Detection Afforded by in Vivo Imaging of Near-Infrared Ii Fluorescence

A Novel Cancer Imaging Method Using Chemiluminescence-Mediated Sonosensitization

Localization of tumor by chemiluminescence probe during photosensitization action.

Tumor Detection with Sonodynamic Chemiluminescence from Atx-70 and Fcla under Ultrasonic Excitation

In vivo ultrasound-induced luminescence molecular imaging

Study on Sonoluminescence Imaging of Living Body

Ultrasound-Activated NIR Chemiluminescence for Deep Tissue and Tumor Foci Imaging

A Novel Cancer Diagnostic Method: Fcla Assisted Sono-Dynamic Diagnosis

Bioluminescence Imaging of Inflammation in Vivo Based on Bioluminescence and Fluorescence Resonance Energy Transfer Using Nanobubble Ultrasound Contrast Agent.

Chemiluminescence Detection from Sonodynamic Action in Vitro and in Vivo

High contrast upconversion luminescence targeted imaging in vivo using peptide-labeled nanophosphors.

Folate Receptor-targeted Aggregation-enhanced Emission Silica Nanoprobe for One-photon in vivo and Two-photon ex vivo Fluorescence Bioimaging

In vivo tumor ultrasound-switchable fluorescence imaging via intravenous injections of size-controlled thermosensitive nanoparticles

In vivo ultrasound-switchable fluorescence imaging

Supramolecular Luminol–AIEgen Nanoparticles for Deep-Tissue-Inflammation Imaging